Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
27 hedge funds and large institutions have $12M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 4 closing their positions.
15% less capital invested
Capital invested by funds: $14.1M → $12M (-$2.12M)
16% less funds holding
Funds holding: 32 → 27 (-5)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$468K |
| 2 |
Renaissance Technologies
New York
|
+$84.3K |
| 3 |
CC
Clearline Capital
New York
|
+$27.1K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$392 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Trading
New York
|
-$222K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$127K |
| 3 |
JP Morgan Chase
New York
|
-$64.3K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$58.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$47.1K |
FRTX Hedge Fund Activity: Q4 2018 in Review
27 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q4 2018, worth a combined $12M — down 15% from $14.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FRTX and 0 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 4 added.
The largest buyer was Sio Capital Management, adding an estimated $468K. The largest seller was Walleye Trading, exiting entirely with an estimated $222K sold.
- 27 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q4 2018, down from 32 in Q3 2018.
- Funds reported $12M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q4 2018, down 15% quarter-over-quarter.
- 0 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q4 2018 and 4 closed out, a net change of -4 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q4 2018 was Sio Capital Management, an estimated $468K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q4 2018 was Walleye Trading, an estimated $222K sold.
Based on aggregated 13F filings for Q4 2018.